These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1504 related articles for article (PubMed ID: 18996393)

  • 1. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of R249S carcinogenic and H168R-R249S suppressor mutations on p53-DNA interaction, a multi scale computational study.
    Rauf SM; Ismael M; Sahu KK; Suzuki A; Koyama M; Tsuboi H; Hatakeyama N; Endou A; Takaba H; Del Carpio CA; Kubo M; Miyamoto A
    Comput Biol Med; 2010 May; 40(5):498-508. PubMed ID: 20403587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations.
    Nikolova PV; Wong KB; DeDecker B; Henckel J; Fersht AR
    EMBO J; 2000 Feb; 19(3):370-8. PubMed ID: 10654936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein.
    Martin AC; Facchiano AM; Cuff AL; Hernandez-Boussard T; Olivier M; Hainaut P; Thornton JM
    Hum Mutat; 2002 Feb; 19(2):149-64. PubMed ID: 11793474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
    Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
    Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
    Sigal A; Rotter V
    Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations.
    Joerger AC; Ang HC; Veprintsev DB; Blair CM; Fersht AR
    J Biol Chem; 2005 Apr; 280(16):16030-7. PubMed ID: 15703170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells.
    Cao Y; Gao Q; Wazer DE; Band V
    Cancer Res; 1997 Dec; 57(24):5584-9. PubMed ID: 9407971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells.
    Rippin TM; Bykov VJ; Freund SM; Selivanova G; Wiman KG; Fersht AR
    Oncogene; 2002 Mar; 21(14):2119-29. PubMed ID: 11948395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
    Brazda V; Muller P; Brozkova K; Vojtesek B
    Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of mutations on peptide models of the DNA binding helix of p53: evidence for a correlation between structure and tumorigenesis.
    Trulson JA; Millhauser GL
    Biopolymers; 1999 Mar; 49(3):215-24. PubMed ID: 9990839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific binding of MAR/SAR DNA-elements by mutant p53.
    Müller BF; Paulsen D; Deppert W
    Oncogene; 1996 May; 12(9):1941-52. PubMed ID: 8649855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.
    Bullock AN; Henckel J; Fersht AR
    Oncogene; 2000 Mar; 19(10):1245-56. PubMed ID: 10713666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.
    Forrester K; Lupold SE; Ott VL; Chay CH; Band V; Wang XW; Harris CC
    Oncogene; 1995 Jun; 10(11):2103-11. PubMed ID: 7784055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro structure-function analysis of the beta-strand 326-333 of human p53.
    Chène P; Mittl P; Grütter M
    J Mol Biol; 1997 Nov; 273(4):873-81. PubMed ID: 9367778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights.
    Merabet A; Houlleberghs H; Maclagan K; Akanho E; Bui TT; Pagano B; Drake AF; Fraternali F; Nikolova PV
    Biochem J; 2010 Mar; 427(2):225-36. PubMed ID: 20113312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
    Di Como CJ; Prives C
    Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAR1, a human anti-p53 single-chain antibody, restores tumor suppressor function to mutant p53 variants.
    Orgad S; Dimant H; Dor-On E; Azriel-Rosenfeld R; Benhar I; Solomon B
    J Immunother; 2010; 33(2):146-54. PubMed ID: 20139776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations.
    Kubicka S; Trautwein C; Niehof M; Manns M
    Hepatology; 1997 Apr; 25(4):867-73. PubMed ID: 9096590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 76.